Prescrire Int. 2010 Aug;19(108):166-7.
Since the late 1990s, umbilical cord blood stem cells have been used to treat some severe haematological disorders. In theory, this type of transplant carries a lower risk of immunological incompatibility. Ten cases of secondary leukaemia following cord blood stem cell transplantation have been published in detail, including 7 cases of acute myeloid leukaemia. The malignancies were diagnosed between 5 and 40 months after transplantation. The patients were severely immunodepressed, and analysis showed that the leukaemias were of donor cell origin. Patients receiving cord blood stem cell grafts, like all transplant recipients, should therefore be monitored for secondary leukaemia.
自20世纪90年代末以来，脐带血干细胞已被用于治疗一些严重的血液系统疾病。理论上，这种类型的移植免疫不相容风险较低。已有10例脐带血干细胞移植后继发性白血病的病例被详细报道，其中包括7例急性髓系白血病。这些恶性肿瘤在移植后5至40个月被诊断出来。患者免疫严重抑制，分析表明白血病起源于供体细胞。因此，接受脐带血干细胞移植的患者，与所有移植受者一样，应监测是否发生继发性白血病。
